Ovarian cancer, version 2.2020

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee May Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Joyce Liu, Haider MahdiLainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O'Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, Anita M. Engh

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes-high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: Carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cordstromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.

Original languageEnglish (US)
Pages (from-to)191-226
Number of pages36
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number2
DOIs
StatePublished - Feb 2 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Ovarian cancer, version 2.2020'. Together they form a unique fingerprint.

Cite this